Celera’s ViroSeq HIV-1 Genotyping System has been cleared by the US Food and Drug Administration (FDA) and is CE Marked for use in detecting HIV mutations that confer resistance to specific types of antiretroviral drugs, as an aid in monitoring and treating HIV infection. ViroSeq can be used for managing therapy changes in HIV-1 infected patients whose drug regimen has failed and in HIV-1 infected individuals at initial presentation, before starting treatment.
ViroSeq’s high throughput processing provides an integrated system from sample preparation to the final interpretive resistance report to aid in treatment decisions. Cleared for use on Applied Biosystems’ 3100 capillary electrophoresis platforms, ViroSeq can be used to detect HIV-1 subtype B viral resistance in samples with a viral load ranging from 2000 to 750,000 copies/mL and provides sequence analysis of the entire HIV-1 protease from codons 1-99 and two-thirds of the reverse transcriptase (RT) gene from codons 1-335.
For more product information, contact your local Abbott Molecular representative